Paradoxical effect of IL-18 therapy on the severe and mild Escherichia coli infections in burn-injured mice

Ann Surg. 2004 Aug;240(2):313-20. doi: 10.1097/01.sla.0000133354.44709.28.

Abstract

Objective: To investigate the effects of IL-18 therapy on severe and mild bacterial infection after burn injury.

Summary background data: IL-18 therapy restores IFN-gamma production in immunosuppressive mice following burn injury and up-regulate host response to LPS and experimental bacterial peritonitis. On the other hand, the overproduction of IFN-gamma could induce an exaggerated inflammation. Therefore, in this study, we focus on the beneficial and deleterious effects of IL-18-induced IFN-gamma and investigate the behavior of IL-18 in infections.

Methods: Burn injury was induced in C57BL/6 mice and then they were i.p. injected with IL-18 (0.2 microg) on alternate days. After 1 week, severe and mild infections were made in mice by an Escherichia coli challenge (5 x 10 CFU and 1 x 10 CFU i.v., respectively).

Results: IL-18 therapy decreased the mortality of burn-injured mice followed by a severe infection, whereas it unexpectedly increased the mortality of burned mice with a mild infection. The IL-18 therapy increased the number of liver mononuclear cells (MNCs), especially NK cells, and greatly up-regulated the impaired IFN-gamma production from the liver and spleen MNCs in mice with severe infection. Both the serum IFN-gamma concentrations recovered while the bacterial count in the liver decreased. In contrast, the serum IFN-gamma concentrations of the burned mice with mild infection did not decrease in comparison to the unburned mice, whereas IL-18 therapy greatly up-regulated the serum IFN-gamma levels in burned mice. However, IL-18 therapy significantly elevated the serum ALT and creatinine levels, thus suggesting that the mortality was induced by an exaggerated form of shock/multiorgan failure. These beneficial and deleterious effects of IL-18 therapy in mice with severe and mild infections, respectively, were all inhibited by anti-IFN-gamma Ab pretreatment.

Conclusion: IL-18 therapy can be a potent therapeutic tool against severe bacterial infection in immunocompromised hosts, but careful attention should also be paid to its adverse effects.

Publication types

  • Comparative Study

MeSH terms

  • Analysis of Variance
  • Animals
  • Biopsy, Needle
  • Burns / complications*
  • Burns / pathology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Escherichia coli / isolation & purification*
  • Escherichia coli Infections / complications
  • Escherichia coli Infections / drug therapy*
  • Immunohistochemistry
  • Injections, Intraperitoneal
  • Injury Severity Score
  • Interferon-gamma / drug effects
  • Interferon-gamma / metabolism*
  • Interleukin-18 / pharmacology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Probability
  • Random Allocation
  • Reference Values
  • Treatment Outcome

Substances

  • Interleukin-18
  • Interferon-gamma